Company intelligence / Profile preview

Changzhou Le Sun Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Sunaciclib, a CDK9 inhibitor, was approved by China's National Medical Products Administration (NMPA) on June 11, 2018 for clinical trial evaluation as a class 1 chemical, with acute myelocytic leukemia as the first indication.

Therapeutic areas: HematologyOncology
Modalities: Small moleculeAntibody-drug conjugateMonoclonal antibodyOncolytic virus therapy
Industry: Biotech

Partnerships

Yabao Pharmaceuticals (2014 partnership for early-stage oncology compound development)

Beyond the preview

Go deeper on Changzhou Le Sun Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changzhou Le Sun Pharmaceuticals.